TRVN - Trevena, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.60
-0.02 (-1.23%)
As of 9:53AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.62
Open1.63
Bid1.61 x 1200
Ask1.62 x 800
Day's Range1.59 - 1.63
52 Week Range1.34 - 2.88
Volume72,028
Avg. Volume1,145,145
Market Cap121.732M
Beta-0.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press12 days ago

    Trevena: 2Q Earnings Snapshot

    The Chesterbrook, Pennsylvania-based company said it had a loss of 13 cents per share. The biopharmaceutical company posted revenue of $2.5 million in the period. The company's shares closed at $1.49. ...

  • Investopedia21 days ago

    Trevena (TRVN): Key Catalysts Coming Into View

    Trevena (NASDAQ: TRVN) is expecting an FDA decision on its pain drug oliceridine on November 2. Furthermore, the FDA has informed the company that it intends to convene an advisory committee meeting to discuss the oliceridine filing (likely in September), which could be a catalyst for shares if positive. Wall Street analysts continue to believe Olinvo will likely be approved by the FDA based on the draft guidelines and two positive pivotal Phase 3 APOLLO studies and ATHENA safety study.

  • Are New Drug Approvals Right Around the Corner for Trevena (TRVN) and Array Biopharma (ARRY)?
    SmarterAnalyst2 months ago

    Are New Drug Approvals Right Around the Corner for Trevena (TRVN) and Array Biopharma (ARRY)?

    Trevena (NASDAQ:TRVN) and Array Biopharma (NASDAQ:ARRY) investors could be celebrating soon enough, should these two drug makers achieve that triumphant FDA approval at the close of a winding biotech road. Between Trevena's opioid asset oliceridine, designed as an intravenous treatment of severe acute pain, and Array's BRAF-mutant melanoma combination therapy candidate encorafenib + binimetinib getting close to final FDA verdicts, two bulls at Cowen are out shedding light on the opportunity ahead. By Cowen's bet, these drug makers are steaming ahead to stamps of FDA approval.

  • Best High Growth NasdaqGS Stocks This Week
    Simply Wall St.2 months ago

    Best High Growth NasdaqGS Stocks This Week

    Investors seeking to increase their exposure to growth should consider companies such as Trevena and Redfin. Analysts are generally optimistic about the future of these stocks, based on how muchRead More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of TRVN earnings conference call or presentation 3-May-18 12:00pm GMT

    Q1 2018 Trevena Inc Earnings Call

  • Trevena signs second international product licensing deal, this time for China
    American City Business Journals3 months ago

    Trevena signs second international product licensing deal, this time for China

    The licensing deal for rights to the Chester County's company opioid pain medicine with a new mechanism of action includes a $2.5 million upfront payment.

  • Associated Press3 months ago

    Trevena: 1Q Earnings Snapshot

    The Chesterbrook, Pennsylvania-based company said it had a loss of 14 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • $3M deal: Trevena signs licensing agreement with South Korean biopharm firm
    American City Business Journals4 months ago

    $3M deal: Trevena signs licensing agreement with South Korean biopharm firm

    The deal involves Trevena experimental pain medicine Olinvo, which it is developing as a safer alternative to traditional opioids. The FDA is reviewing a new drug application Trevena filed last year to market the drug in the United States.

  • Founding CEO of Trevena biopharm firm to retire
    American City Business Journals4 months ago

    Founding CEO of Trevena biopharm firm to retire

    The former GlaxoSmithKline executive has led the company, which is working on a new type of pain medicine, for the past decade. Her successor will be promoted from within the company.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of TRVN earnings conference call or presentation 7-Mar-18 1:00pm GMT

    Q4 2017 Trevena Inc Earnings Call

  • GuruFocus.com5 months ago

    3 Stocks Move Wednesday

    Stocks advance on stronger-than-expected results

  • Associated Press5 months ago

    Trevena reports 4Q loss

    On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 24 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Trevena Inc (NASDAQ:TRVN): When Will It Breakeven?
    Simply Wall St.5 months ago

    Trevena Inc (NASDAQ:TRVN): When Will It Breakeven?

    Trevena Inc’s (NASDAQ:TRVN): Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The US$120.24M market-cap company’s lossRead More...

  • 7 High-Risk, High-Reward Stocks to Buy Now
    InvestorPlace7 months ago

    7 High-Risk, High-Reward Stocks to Buy Now

    The company will next report results on Feb. 9, before the bell. Analysts are looking for earnings of 44-cents-per-share on revenues of $4 billion. When the company last reported on Nov. 10, a loss of 33-cents-per-share beat estimates by 10 cents on a 1.8% decline in revenues.

  • Trevena, Inc. (TRVN) Jumps: Stock Rises 11.7%
    Zacks7 months ago

    Trevena, Inc. (TRVN) Jumps: Stock Rises 11.7%

    Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares nearly 12% on the day amid huge volumes.

  • GuruFocus.com7 months ago

    3 Stocks Move Wednesday

    Commercial Metals, Trevena rise, Ralph Lauren falls

  • 24/7 Wall St.7 months ago

    Trevena Surges With FDA Decision

    Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.

  • Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up
    Zacks7 months ago

    Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up

    FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.

  • InvestorPlace7 months ago

    3 Stocks to Watch on Wednesday: Moneygram International Inc (MGI), Trevena Inc (TRVN) and Tetraphase Pharmaceuticals Inc (TTPH)

    Several companies made headlines after hours Tuesday, including Moneygram International Inc (NASDAQ:MGI), Trevena Inc (NASDAQ:TRVN) and Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Moneygram International’s big-money deal did not go through. This isn’t the first deal between a Chinese party and the U.S. that was rejected by the administration of U.S. President Donald Trump.

  • Thomson Reuters StreetEvents9 months ago

    Edited Transcript of TRVN earnings conference call or presentation 7-Nov-17 1:00pm GMT

    Q3 2017 Trevena Inc Earnings Call

  • TheStreet.com9 months ago

    Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

    The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

  • American City Business Journals10 months ago

    Chesco biopharm firm cuts 21 jobs as part of restructuring

    Chester County biopharmaceutical company Trevena Inc. is cutting 21 jobs and halting its investments in early-stage research under a restructuring to focus its resources on its lead new drug candidate. The workforce reduction represents 30 percent of the Chesterbook, Pa., company's staff. Trevena's immediate focus will be on the potential approval and commercialization of Olinvo, its new drug candidate under development as a potential treatment to manage moderate-to-severe acute pain.